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A
cute lower respiratory infections, which broadly 
include pneumonia and bronchiolitis, are still the 
leading cause of childhood mortality. ALRI contrib-
uted to 18% of all deaths in children younger than five 
years of age in 2008 [1], and the main pathogens respon-
sible for high mortality were Streptococcus pneumoniae, Hae-
mophilus influenzae and respiratory syncytial virus [2-4]. In 
addition, meningitis was estimated to contribute up to 
200 000 deaths each year, and influenza anywhere between 
25 000 and 110 000 [1,5]. It is widely acknowledged that 
a major portion of this mortality should be avoidable if uni-
versal coverage of all known effective interventions could 
be achieved. However, some evaluations of the implemen-
tation of World Health Organization’s (WHO) Integrated 
Management of Childhood Illness (IMCI) strategy, which 
promotes improved access to a trained health provider who 
can administer “standard case management”, have shown 
somewhat disappointing results [6-8]. Only a minority of 
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all children with life-threatening episodes of pneumonia, 
meningitis and influenza in developing countries have ac-
cess to trained health providers and receive appropriate 
treatment [6-8]. Thus, novel strategies for control of pneu-
monia that balance investments in scaling up of existing 
interventions and the development of novel approaches, 
technologies and ideas are clearly needed.
EMERGING INTERVENTIONS AGAINST 
CHILDHOOD PNEUMONIA, MENINGITIS 
AND INFLUENzA
Several recent studies quantified the burden of child mor-
tality due to childhood infections [1] and sub-divided it 
further according to the causing infectious pathogens [2-5]. 
In a series of papers that followed, we systematically re-
viewed the available information relevant to the emerging 
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interventions against childhood pneumonia, meningitis 
and influenza [9-14]. We defined the list of emerging in-
terventions of interest as follows: (i) the first set of emerg-
ing interventions was suggested by the officers from the Bill 
and Melinda Gates Foundation (BMGF) and it was based 
on strategic priorities that were being discussed at the 
Foundation in the year 2009; (ii) additional ideas were pro-
posed by our team at the University of Edinburgh, after 
provisionally reviewing the literature on emerging interven-
We conducted an expert panel exercise to 
assess feasibility and potential effectiveness 
of 29 emerging health interventions against 
childhood pneumonia, meningitis and influ-
enza. 20 leading international experts from 
international agencies, industry, basic sci-
ence and public health research took part in 
a CHNRI priority setting process. They used 
12 different criteria relevant to successful 
development  and  implementation  and 
showed most collective optimism towards 
improving low-cost pneumococcal conju-
gate vaccines, antibiotic pediatric formula-
tions, the development of common-protein 
pneumococcal vaccines and multivalent 
meningococcal vaccines.
Table 1 The consolidated list of 29 emerging interventions against childhood pneumonia, meningitis and influenza
  1 Low-cost polysaccharide conjugate vaccines for Pneumococcus (low-cost: US$ 3.50 per dose)
  2 Low cost, cross-protective common protein vaccines for Pneumococcus
  3 Low cost, cross-protective common protein vaccines for seasonal influenza (existing flu vaccines should be considered as a current intervention)
  4 Monoclonal antibodies for passive immunization against RSV
  5 Anti-RSV vaccine for use in infants
  6 Anti-RSV vaccine for use in pregnant women
  7 Meningitis A conjugate vaccine
  8 Multivalent meningococcal vaccines
  9 Combination vaccines: meningococcal + other vaccines
10 Needle-free versions of current measles vaccines
11 Heat stable versions of current measles vaccines
12 Oxygen delivery systems for low-resource settings
13 Low cost ventilatory support
14 Non-liquid pediatric antibiotic formulations for use in large scale programmes in appropriate dose
15 Vaccines against S. aureus
16 Passive immunization against S. aureus
17 Combination vaccines against multiple respiratory viruses
18 Maternal vaccination to protect neonates against neonatal sepsis: E coli and Klebsiella
19 Maternal vaccination to protect neonates against neonatal sepsis: Streptococcus B and S. aureus
20 Rapid diagnostic test for bacterial infections in children
21 Rapid multiplex assay for etiology-specific diagnosis in children
22 Rapid multiplex assay for etiology-specific diagnosis in young infants
23 Rapid diagnostic test to predict severe outcome of pneumonia episode
24 Maternal vaccination for infectious agents relevant in infants (eg, PC, Hib, influenza)
25 Effective mucosal (oral or rectal) antibiotics for neonatal infections
26 Immunomodulating agents to stimulate innate immunity
27 Surfactant replacement therapy
28 Novel interventions to reduce indoor air pollution
29 Water-free solution for hand disinfection to reduce transmission of respiratory pathogens
RSV – respiratory syncytial virus, PC – pneumococcus, Hib – Haemophilus influenzae Type B
tions against childhood infections; (iii) the third set of 
emerging interventions was suggested by the 20 interna-
tional experts invited to take part in the CHNRI expert pan-
el meeting (see later). We eventually agreed to evaluate 29 
emerging interventions that seemed feasible for reaching 
the implementation within a 10-year period (Table 1). We 
aimed to be inclusive and open-minded in their selection 
because some of them may still be far from implementation.
THE ExPERT OPINION ExERCISE
The CHNRI methodology for priority setting in health re-
search (and technologies) investments was proposed as a 
systematic tool that can be used by those who develop re-
search policy and/or invest in health research [15-18]. It 
should assist them to understand (i) the full spectrum of 
research investment options; (ii) the potential risks and 
benefits that can result from investments in different re-
search options; and (iii) the likelihood of achieving reduc-
tions of persisting burden of disease and disability through 
investments in health research and health technologies. The 
CHNRI methodology has 3 stages: input from investors/
policy-makers (who define the context and criteria for pri-
ority setting); input from technical experts (who propose, 
list in a systematic way, and then score different research 
investment options against a pre-defined set of criteria); and 
input from other stakeholders (weighing the criteria ac-
cording to wider societal system of values). The method has 
been described in detail elsewhere and many examples of 
its implementation are publically available [19-22].V
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The expert opinion exercise focused only on emerging in-
terventions and a broad, long-term (downstream) context/
vision. We invited 20 leading international experts from 
international agencies, industry, basic science and public 
health research to Dubrovnik, Croatia, in September 2009. 
The invited experts provided opinion on how the 29 cho-
sen emerging interventions satisfy a number of criteria rel-
evant to prioritization of support to emerging interventions 
against childhood infections. Based on a modified CHNRI’s 
conceptual framework, 12 criteria for prioritization were 
developed for emerging interventions: (i) answerability (in 
an ethical way); (ii) low development cost; (iii) low prod-
uct cost; (iv) low implementation cost; (v) likelihood of ef-
ficacy and effectiveness; (vi) likelihood of deliverability; 
(vii) likelihood of affordability; (viii) likelihood of sustain-
ability; (ix) maximum potential impact on mortality bur-
den reduction; (x) likelihood of acceptability to health 
workers; (xi) likelihood of acceptability to end users; (xii) 
predicted impact on equity. Further details about the mod-
ified CHNRI framework with the 12 criteria used for the 
expert panel meeting in Dubrovnik in 2009, and the pro-
cess of the expert opinion exercise, are available from the 
corresponding author upon request.
The first task for the experts was to read the background 
information assembled about the 29 emerging interven-
tions in a 285-page landscape review, later published as a 
series of papers [9-14]. The second task was to participate 
in the expert panel meeting where, over the course of 5 
days and a total of 10 discussion sessions, the experts were 
told why each of the 12 criteria was chosen, and then they 
discussed how to apply them to each of the 29 emerging 
interventions. They were free to challenge all information 
provided to them in a background document and to share 
further personal knowledge or opinion with the group. 
Notes of their input were taken and the landscape review 
was being continuously amended. After each discussion 
session the experts were invited to score, independently of 
each other, all emerging interventions according to the 12 
agreed CHNRI criteria. For each of the 29 emerging inter-
ventions and each criterion, each expert answered ques-
tions targeted to assess the likelihood of the proposed 
emerging interventions to comply with the priority-setting 
criterion. A summarized version of those questions is pre-
sented in Table 2. The full version of questionnaires that 
were used is available upon request from the correspond-
ing author.
Table 2 A summarized version of questions used to assess whether proposed 29 interventions satisfy the 12 priority-setting criteria
anSwerability (“1” For yeS; “0” For no; “0.5” For undecided)
 Do we have a sufficient research and development capacity to make the intervention available on the market by 2020?
 Do we have a sufficient level of funding support to make the intervention available on the market by 2020?
 Would you say that it is likely that the remaining technical hurdles can be overcome to make the intervention available on the market by 2020?
coSt oF development (in uS$) (“1” For yeS; “0” For n; “0.5” For undecided)
 How much will it cost to get from the current stage of development to commercial availability of each emerging intervention below?
a.<US$1 billion, b.<US$ 500 million, c.<US$ 100 million
coSt oF implementation (in uS$) (“1” For yeS; “0” For n; “0.5” For undecided)
 Is it likely to be a low-cost intervention (ie, <3.50 US$ per unit?)
 Can we use the existing delivery mechanisms without major modifications (eg, training, infrastructure)?
 Is achievement of a near-universal coverage likely to be affordable to most developing countries?
likelihood oF eFFicacy (0%-100%)
   Please assess the likelihood (0%-100%) that adequately powered randomized controlled trials of the interventions listed below (ROWS), conducted 
in developing countries, would consistently show statistically significant reduction in cause-specific mortality from each of the four causes of death 
listed below (COLUMNS).
a. Pneumonia, b. Meningitis, c. Neonatal sepsis, d. Influenza
likelihood oF maximum potential impact on diSeaSe burden
   Please predict, for each of the 4 causes of death below (COLUMNS), the proportion of deaths in children under five years of age due to that cause 
that could be averted if the complete coverage with the emerging interventions listed below (ROWS) could be achieved?
a. Pneumonia, b. Meningitis, c. Neonatal sepsis, d. Influenza
deliverability and SuStainability (“1” For yeS; “0” For n; “0.5” For undecided)
   Taking into account (i) the infrastructure and resources required to deliver emerging interventions listed below (eg, human resources, health facili-
ties, communication and transport infrastructure); (ii) the resources likely to be available to implement the emerging interventions at the time of 
introduction; (iii) overall capacity of the governments (eg, adequacy of government regulation, monitoring and enforcement; governmental inter-
sectoral coordination), and (iv) internal and external partnership required for delivery of interventions (eg, partnership with civil society and exter-
nal donor agencies), would you say that the emerging interventions would be?
a. Deliverable at the time of introduction, b. Affordable at the time of introduction, c. Sustainable for at least 10 y after the time of introduction
  Assessing Readiness of Health Systems to take Existing and Emerging Interventions to High Coverage Globally (90% Urban / 80% Rural) at this 
Point and at the Time of their Introduction (“1” – we are ready (or we will be ready); “0.5” – we may be getting closer, but are not quite ready; “0” – we will 
not be ready;)
   Please study the existing and emerging interventions against childhood pneumonia, meningitis, sepsis and influenza listed below (ROWS) and the 
6 “building blocks of health systems” from the WHO framework (COLUMNS). Please indicate your assessment of the level of readiness to take each 
of the interventions below to high coverage globally (90% urban / 80% rural) at this point in time, and following their introduction at some future 
point (the latter is only needed for those interventions that are NOT already available).
a. Service delivery, b. Health workforce, c. Health information systems, d. Med. products, e. Vaccines and technologies, f. Health systems financing, 
g. Leadership and governance
acceptability and equity (“1” For yeS; “0” For n; “0.5” For undecided)
   Taking into account the overall context, intervention complexity, health workers’ behavior and the end-user population at the time of introduction,
a. Would health workers be likely to comply with implementation guidelines?, b. Would end-users be likely to fully accept the intervention?, c. 
Would you say that the proposed intervention has the overall potential to improve equity after 10 y following the introduction?V
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The second level of priority was assigned to 
improvements in existing vaccines to enable 
needle-free delivery and heat stability, and 
to evaluations of maternal immunization, im-
proved use of oxygen systems and the de-
velopment of combination vaccines and 
vaccines against major viral pathogens. Pas-
sive immunization, action on risk factors 
such as indoor air pollution or poor sanita-
tion, or development of vaccines against 
sepsis-causing bacterial pathogens received 
the lowest scores. The exercise suggested 
that most of the emerging interventions are 
still not feasible.
The process of expert assessment (scoring) of emerging in-
terventions was performed as follows: all the experts an-
swered the questionnaire related to each criterion by an-
swering ‘Yes’ (1 point) or ‘No’ (0 points). They were also 
allowed to declare an informed but undecided answer (0.5 
points) or declare themselves insufficiently informed to an-
swer the question (missing input). Thus, the proposed re-
search questions got a score from 20 experts for each of the 
12 criteria. This score was “the proportion of maximum 
possible points scored when an answer was given” (ie, ex-
cluding the missing input), and it was a number between 
0 and 100%. This number represented a direct measure of 
“collective optimism” of all the scorers toward each emerg-
ing intervention, given the criterion in question. Each of 
the 29 proposed emerging interventions received 12 crite-
rion-specific scores, each ranging between 0%-100%. The 
criterion over which the experts were most uncertain was 
the cost of implementation, which was deemed very diffi-
cult to predict by most of them. We agreed that a separate 
exercise should be conducted in a low-income setting to 
improve understanding of the factors that affect this cost, 
and this has been done later [23].
The overall research priority score (RPS) for each interven-
tion was computed as the mean value of 9 intermediate 
scores for 9 selected criteria. The reason why all 12 criteria 
weren’t used is because CHNRI exercise requires that the 
criteria need to be relatively independent of each other 
(similar to principal component analysis in statistics). In 
this exercise, we were interested in different components 
of the cost (development cost, product cost, implementa-
tion cost and affordability), but those 4 cri-
teria are in fact a single criterion, and if all 
4 were kept in the exercise, this would give 
an undue 4-fold ‘weight’ to one criterion at 
the expense of the others. The experts 
agreed that the most important of the 4 cost-
related criteria related to emerging interven-
tions is ‘development cost’, because costs of 
product and implementation can be met 
through other mechanisms (such as GAVI, 
PEPFAR, Global Fund, etc.). Thus, the cost 
of product, cost of implementation and af-
fordability were kept out of the final score 
calculation. The exact scores given to all 29 
emerging interventions are presented in Ta-
ble 3. The final report on CHNRI exercise 
has received the approval of the experts, 
among whom some (mainly from the indus-
try) wished to remain anonymous.
THE MAIN MESSAGES
Table 3 shows that the experts declared most of their col-
lective optimism to improvement of low-cost pneumococ-
cal conjugate vaccines. This was followed by the develop-
ment of non-liquid and mucosal antibiotic pediatric 
formulations with improved deliverability and acceptabil-
ity in low resource settings. The development of common-
protein pneumococcal vaccines and multivalent meningo-
coccal vaccines were seen as the third most promising 
emerging intervention. Following this cluster at the top, 
the second level of priority was assigned to improvements 
Photo: Courtesy of Alasdair Campbell, private collectionV
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Table 3 The results of the CHNRI exercise: 29 emerging interventions with 9 intermediate scores and an overall research priority score
rank emerging intervention anSwer-
ability
low 
develop-
ment 
coSt
likeli-
hood oF 
eFFicacy
max 
burden 
reduction 
potential
deliver-
able
SuStain-
able
accept-
able to 
health 
workerS
accept-
able 
to end 
uSerS
impact 
on equity
reSearch 
inveSt-
ment 
priority 
Score
1 Low-cost polysaccharide conjugate vaccines for pneumococcus 0.96 0.80 0.81 0.32 0.86 0.86 1.00 0.90 1.00 0.84
2 Non-liquid pediatric antibiotic formulations for use in large-
scale programs in appropriate dose 0.76 0.90 0.78 0.30 0.86 0.95 0.85 1.00 0.95 0.82
3 Low cost, cross-protective common protein vaccines for pneu-
mococcus 0.72 0.50 0.83 0.36 0.86 0.85 1.00 0.90 1.00 0.78
4 New mucosal (oral and rectal) antibiotics for pneumonia and 
neonatal infections 0.58 0.70 0.60 0.22 0.80 0.90 1.00 0.94 0.89 0.74
5 Meningitis A conjugate vaccine 0.88 0.90 0.18 0.04 0.95 0.77 1.00 0.94 0.95 0.74
6 Multivalent meningococcal vaccines 0.75 0.70 0.17 0.07 0.95 0.77 1.00 1.00 0.95 0.71
7 Heat stable versions of current vaccines targeting pneumonia 
(eg, measles and others) 0.46 0.50 0.52 0.11 0.91 0.91 0.85 1.00 1.00 0.69
8 Needle-free versions of current vaccines targeting pneumonia 
(eg, measles and others) 0.57 0.50 0.49 0.10 0.86 0.91 0.85 0.95 0.95 0.69
9 Maternal vaccination for infectious agents relevant in infants (eg, 
PC, Hib, influenza) 0.66 0.90 0.59 0.22 0.60 0.70 0.94 0.72 0.78 0.68
10 Low cost, cross-protective common protein vaccines for season-
al flu (existing vaccines excluded) 0.61 0.50 0.52 0.15 0.82 0.75 0.90 0.80 0.90 0.66
11 Water-free solution for hand disinfection to reduce transmission 
of respiratory pathogens 0.88 1.00 0.69 0.18 0.65 0.50 0.67 0.56 0.67 0.64
12 Oxygen delivery systems for low-resource settings 0.81 1.00 0.77 0.21 0.65 0.55 0.65 0.70 0.44 0.64
13 Combination vaccines: meningococcal + other EPI vaccines 0.36 0.40 0.39 0.12 0.91 0.86 0.95 0.90 0.85 0.64
14 Vaccines against additional pathogens that cause pneumonia – 
multiple respiratory viruses 0.48 0.40 0.69 0.24 0.70 0.70 0.85 0.80 0.75 0.62
15 Anti-RSV vaccine for use in infants 0.58 0.50 0.62 0.14 0.56 0.61 0.90 0.67 0.72 0.59
16 Point-of-care diagnostic for bacterial infections in children 0.61 0.60 0.59 0.26 0.55 0.64 0.55 0.65 0.70 0.57
17 Point-of-care diagnostic for etiology-specific pathogen in young 
infants 0.50 0.60 0.61 0.23 0.50 0.64 0.61 0.65 0.72 0.56
18 Low cost ventilatory support 0.54 0.70 0.73 0.16 0.45 0.45 0.75 0.75 0.44 0.55
19 Anti-RSV vaccine for use in pregnant women 0.43 0.50 0.57 0.11 0.56 0.56 0.85 0.72 0.67 0.55
20 Vaccines against additional pathogens that cause pneumonia – 
S. aureus 0.47 0.60 0.40 0.12 0.64 0.55 0.85 0.75 0.55 0.55
21 Point-of-care diagnostic to distinguish viral and bacterial infec-
tions in young infants 0.36 0.60 0.61 0.20 0.50 0.64 0.61 0.65 0.72 0.54
22 Point-of-care diagnostic to predict severe outcome of pneumo-
nia episode 0.29 0.40 0.63 0.32 0.41 0.59 0.67 0.85 0.72 0.54
23 Novel interventions to reduce indoor air pollution 0.64 0.90 0.54 0.12 0.50 0.40 0.42 0.61 0.56 0.52
24 Immunomodulating agents to stimulate innate immunity 0.51 0.50 0.43 0.10 0.38 0.38 0.75 0.81 0.50 0.48
25 Monoclonal antibodies for passive immunization against RSV 0.71 0.90 0.63 0.09 0.17 0.17 0.65 0.56 0.33 0.47
26 Maternal vaccination to protect neonates against major causes 
of neonatal sepsis – Streptococcus B, Staphylocossus 0.25 0.50 0.20 0.07 0.45 0.50 0.85 0.75 0.55 0.46
27 Surfactant replacement therapy 0.62 0.80 0.41 0.08 0.33 0.19 0.63 0.69 0.38 0.46
28 Maternal vaccination to protect neonates against major causes 
of neonatal sepsis – E coli, Klebsiela 0.25 0.40 0.25 0.05 0.45 0.50 0.85 0.70 0.50 0.44
29 Passive immunization against Staphylococcus 0.58 0.60 0.32 0.07 0.33 0.33 0.65 0.72 0.28 0.43
RSV – respiratory syncytial virus, PC – pneumococcus, Hib – Haemophilus influenzae Type B
in existing vaccines (eg, measles or H. influenzae type b) to 
enable needle-free delivery and heat stability. Similar over-
all scores were given to evaluations of maternal immuniza-
tion, improved use of oxygen systems and the development 
of combination vaccines and vaccines against major viral 
pathogens. The next level of priority was assigned to vari-
ous diagnostic tools, the impact of which is currently lim-
ited with sub-optimal levels of access to care, care-seeking 
behavior and the availability of 1st and 2nd line antibiot-
ics. Interventions that proposed passive immunization, ac-
tion on risk factors such as indoor air pollution or poor 
sanitation, or development of vaccines against sepsis-caus-
ing bacterial pathogens such as S. aureus or E coli received 
the lowest scores (Table 3).
An extended version of the results of the CHNRI process 
with the current status of each emerging interventions’ de-
velopment, the key challenges that remain to be addressed, 
the visual representation of scores given by the expert pan-
el to each intervention and the assessment of potential ef-
fectiveness of each intervention is available in the series of 
papers published elsewhere [9-14]. It should be noted that 
the assessment of potential effectiveness (Table 3) can also 
range from 0%-100%, but its interpretation is different than 
of the other 11 criteria; rather than measuring collective op-
timism, it actually predicts the proportion of mortality bur-
den that could be averted through implementation.
Pneumococcal conjugate vaccines, which were treated as 
emerging interventions back in 2009 because of a very low 
uptake in low and middle income countries at the time, 
achieved scores over 80% for all criteria apart from “low 
product cost” – which indeed ended up being the main 
point of discussion once they were introduced. In compar-V
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ison, common protein pneumococcal vaccines are still held 
back by concerns over answerability (although it is getting 
closer to 80%), and over all criteria related to their future 
cost. Other interventions show quite different score pro-
files. For example, anti-RSV vaccine for use in infants failed 
on all criteria apart from “acceptance for health workers”, 
whereas monoclonal antibodies for passive immunization 
against RSV failed entirely on product cost, affordability 
and sustainability concerns, although product develop-
ment cost was considered feasible. The introduction of ox-
ygen systems was considered answerable and did not suffer 
from major cost concerns, but these systems were not 
deemed sustainable, sufficiently acceptable and equitable. 
In comparison, common protein flu vaccines were consid-
ered sustainable, acceptable and equitable, but there were 
still concerns about answerability and costs of development 
and of the final product.
CONCLUSION
In accordance with other similar exercises with CHNRI 
methodology the process showed some clear advantages. 
The context and the criteria were transparent and the man-
agement of the process was overseen by the funding agen-
cy (BMGF) over its entire duration. This kind of partner-
ship should result in better understanding and promote 
ownership and commitment to the main messages of the 
expert opinion exercise. The scoring process was highly 
systematic and structured. It was free from undue influence 
from prominent members within the expert group, because 
all the experts submitted their opinions and scores inde-
pendently from each other. The varied mix of the experts 
from different backgrounds ensured that the scientific as-
sessment of the research priorities is combined with a view 
of the broader community in which the priorities would be 
implemented. The entire process from the initial to the fi-
nal stages was documented and can be viewed and chal-
lenged at any point in time. The final result of the process 
was a simple quantitative outcome (“research priority 
score”), which measured the “value” of each research op-
tion when all the criteria and views were taken into ac-
count. This “value” can be combined with the predicted 
cost of further research and development needs in order to 
derive an optimal mix of emerging interventions to be 
funded from a limited budget.
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